BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 33566253)

  • 21. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia.
    Gang EJ; Hsieh YT; Pham J; Zhao Y; Nguyen C; Huantes S; Park E; Naing K; Klemm L; Swaminathan S; Conway EM; Pelus LM; Crispino J; Mullighan CG; McMillan M; Müschen M; Kahn M; Kim YM
    Oncogene; 2014 Apr; 33(17):2169-78. PubMed ID: 23728349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting Wnt/β-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia.
    Evangelisti C; Chiarini F; Cappellini A; Paganelli F; Fini M; Santi S; Martelli AM; Neri LM; Evangelisti C
    J Cell Physiol; 2020 Jun; 235(6):5413-5428. PubMed ID: 31904116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes.
    Liu Z; Ding K; Li L; Liu H; Wang Y; Liu C; Fu R
    Biomed Pharmacother; 2016 Oct; 83():1032-1037. PubMed ID: 27541047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histone deacetylase inhibitor chidamide promotes reactivation of latent human immunodeficiency virus by introducing histone acetylation.
    Kuai Q; Lu X; Qiao Z; Wang R; Wang Y; Ye S; He M; Wang Y; Zhang T; Wu H; Ren S; Yu Q
    J Med Virol; 2018 Sep; 90(9):1478-1485. PubMed ID: 29704439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. E-cadherin gene re-expression in chronic lymphocytic leukemia cells by HDAC inhibitors.
    Jordaan G; Liao W; Sharma S
    BMC Cancer; 2013 Feb; 13():88. PubMed ID: 23432814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma.
    Que Y; Zhang XL; Liu ZX; Zhao JJ; Pan QZ; Wen XZ; Xiao W; Xu BS; Hong DC; Guo TH; Shen LJ; Fan WJ; Chen HY; Weng DS; Xu HR; Zhou PH; Zhang YZ; Niu XH; Zhang X
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HCV Core protein represses DKK3 expression via epigenetic silencing and activates the Wnt/β-catenin signaling pathway during the progression of HCC.
    Wang X; Zhou Y; Wang C; Zhao Y; Cheng Y; Yu S; Li X; Zhang W; Zhang Y; Quan H
    Clin Transl Oncol; 2022 Oct; 24(10):1998-2009. PubMed ID: 35768685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dickkopf-3 expression is a marker for neuroblastic tumor maturation and is down-regulated by MYCN.
    Koppen A; Ait-Aissa R; Koster J; Øra I; Bras J; van Sluis PG; Caron H; Versteeg R; Valentijn LJ
    Int J Cancer; 2008 Apr; 122(7):1455-64. PubMed ID: 18059033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Change in gene expression profiles of secreted frizzled-related proteins (SFRPs) by sodium butyrate in gastric cancers: induction of promoter demethylation and histone modification causing inhibition of Wnt signaling.
    Shin H; Kim JH; Lee YS; Lee YC
    Int J Oncol; 2012 May; 40(5):1533-42. PubMed ID: 22246241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chidamide and mitomycin C exert synergistic cytotoxic effects against bladder cancer cells in vitro and suppress tumor growth in a rat bladder cancer model.
    Wang SC; Yu CY; Wu YC; Chang YC; Chen SL; Sung WW
    Cancer Lett; 2022 Apr; 530():8-15. PubMed ID: 35033588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl‑2 pathway.
    Zhang H; Chi F; Qin K; Mu X; Wang L; Yang B; Wang Y; Bai M; Li Z; Su L; Yu B
    Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33649847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Wnt signalling is a bi-directional vulnerability of cancer cells.
    Duffy DJ; Krstic A; Schwarzl T; Halasz M; Iljin K; Fey D; Haley B; Whilde J; Haapa-Paananen S; Fey V; Fischer M; Westermann F; Henrich KO; Bannert S; Higgins DG; Kolch W
    Oncotarget; 2016 Sep; 7(37):60310-60331. PubMed ID: 27531891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor.
    Li Y; Chen K; Zhou Y; Xiao Y; Deng M; Jiang Z; Ye W; Wang X; Wei X; Li J; Liang J; Zheng Z; Yao Y; Wang W; Li P; Xu B
    Curr Cancer Drug Targets; 2015; 15(6):493-503. PubMed ID: 26282548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma.
    Xue K; Wu JC; Li XY; Li R; Zhang QL; Chang JJ; Liu YZ; Xu CH; Zhang JY; Sun XJ; Gu JJ; Guo WJ; Wang L
    Cell Death Dis; 2021 Oct; 12(10):900. PubMed ID: 34599153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against nonsmall-cell lung cancer.
    Shieh JM; Tang YA; Hu FH; Huang WJ; Wang YJ; Jen J; Liao SY; Lu YH; Yeh YL; Wang TW; Lin P; Wang YC
    Int J Cancer; 2017 May; 140(10):2375-2386. PubMed ID: 28233309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells.
    Liu L; Chen B; Qin S; Li S; He X; Qiu S; Zhao W; Zhao H
    Biochem Biophys Res Commun; 2010 Feb; 392(2):190-5. PubMed ID: 20060381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel histone deacetylase inhibitor LT-548-133-1 induces apoptosis by inhibiting HDAC and interfering with microtubule assembly in MCF-7 cells.
    Xue J; Wu G; Ejaz U; Akhtar F; Wan X; Zhu Y; Geng A; Chen Y; He S
    Invest New Drugs; 2021 Oct; 39(5):1222-1231. PubMed ID: 33788074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer.
    Zhang N; Sun P; Jin H; Yang Y; Zhao Q; Zhou L; Guo L; Yang X; Lu L
    Anticancer Drugs; 2020 Aug; 31(7):702-708. PubMed ID: 32701251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy.
    Gao S; Li X; Zang J; Xu W; Zhang Y
    Anticancer Agents Med Chem; 2017; 17(6):802-812. PubMed ID: 27592546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA-95-3p promoted the development of prostatic cancer via regulating DKK3 and activating Wnt/β-catenin pathway.
    Xi M; Cheng L; Hua W; Zhou YL; Gao QL; Yang JX; Qi SY
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1002-1011. PubMed ID: 30779066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.